- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04571619
HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis (HOPE)
A Randomized Clinical Trial to Evaluate Non-Pharmacologic and Pharmacologic Approaches for Reducing Pain and Opioid Use Among Patients Treated With Maintenance Hemodialysis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Natalie Kuzla, MA
- Phone Number: 2155732935
- Email: nkuzla@pennmedicine.upenn.edu
Study Contact Backup
- Name: Leah Bernardo
- Phone Number: 2157464755
- Email: lleah@pennmedicine.upenn.edu
Study Locations
-
-
Connecticut
-
West Haven, Connecticut, United States, 06516
- West Haven VA Healthcare System
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico
-
-
New York
-
New York, New York, United States, 10010
- New York University
-
New York, New York, United States, 10010
- VA NY Harbor Healthcare System
-
New York, New York, United States, 10021
- Rogosin Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Durham VA Healthcare System
-
-
Oregon
-
Portland, Oregon, United States, 97239
- VA Portland Healthcare System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75216
- Dallas VA Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Undergoing in-center maintenance hemodialysis for ≥90 days
- English- or Spanish-speaking
- Chronic pain defined as a response of "Most days" or "Every day" to the following question: "In the past 3 months, how often have you had pain?" Answer options: Never, Some days, Most days, Every day
- Current Pain, Enjoyment of Life and General Activity Scale (PEG) score ≥ 4
- Willing to provide informed consent
- Willing to allow research team to obtain opioid pharmacy refill data
- Willing to allow research team to contact and work with their opioid prescriber
Exclusion Criteria:
- Current opioid use disorder
- Current use of heroin
- Current non-opioid substance use disorder with the exception of tobacco use disorder
- Current use of methadone, buprenorphine, or naltrexone for opioid use disorder
- Current receipt of hospice care
- Cognitive impairment that, in the judgement of the research team, precludes trial participation
- Active suicidal intent
- Unstable bipolar disorder, schizophrenia, post-traumatic stress disorder, or other psychotic disorder
- Life expectancy < 6 months
- Expected to receive a kidney transplant, transfer to another dialysis facility, or transition to home dialysis within 6 months
- Current incarceration
- Any other condition that the investigator considers precludes participation in the clinical trial
Subgroup with Current or Recent Opioid Use During eligibility screening all potential participants will have opioid use ascertained using the timeline follow back approach. The trial will enroll at least 300 participants (among the 640 total study participants) with current or recent opioid use defined as patient-reported prescription opioid use during at least 3 of the past 6 months. The number of participants in the opioid use subgroup will be monitored throughout the trial enrollment period. If the rate of enrollment into the opioid use subgroup is lower than targeted, trial enrollment will be restricted to individuals meeting the opioid use criteria as long as necessary to ensure that the total enrollment target for the trial is not met without reaching the opioid use subgroup target.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care
|
|
Active Comparator: Buprenorphine
|
At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine.
Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations.
Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors.
Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine.
All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
|
Active Comparator: Pain Coping Skills Training
|
The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills.
For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use.
During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video).
During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone.
The telehealth component will consist of weekly sessions, each lasting 45-50 minutes.
The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes.
Both components of the intervention will be available in English and Spanish.
|
No Intervention: No Buprenorphine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain interference
Time Frame: The primary outcome of pain interference will be ascertained at Week 12 coinciding with the end of the PCST weekly coaching sessions.
|
Pain interference as measured by the Brief Pain Index (BPI) Interference Scale.
This is typically scored as the mean of the seven items.
Lowest score - 0; Highest score - 10.
A higher score is worse.
|
The primary outcome of pain interference will be ascertained at Week 12 coinciding with the end of the PCST weekly coaching sessions.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain intensity
Time Frame: Weeks 12, 24, and 36
|
Pain intensity as measured by the Brief Pain Index (BPI) Severity Scale.
Lowest score - 0; Highest score - 40.
A higher score is worse.
|
Weeks 12, 24, and 36
|
Pain catastrophizing
Time Frame: Weeks 12, 24, and 36
|
Pain catastrophizing will be measured using the Pain Catastrophizing Scale (PCS) Short Form (SF) 6. Lowest score - 0; Highest score - 24.
A higher score is worse.
|
Weeks 12, 24, and 36
|
Opioid use
Time Frame: Weeks 12, 24, and 36
|
Weeks 12, 24, and 36
|
|
Rate of falls
Time Frame: Throughout the 36-week follow-up
|
Event rate; # per patient year
|
Throughout the 36-week follow-up
|
Rate of hospitalizations
Time Frame: Throughout the 36-week follow-up
|
Event rate; # per patient year
|
Throughout the 36-week follow-up
|
Death
Time Frame: Throughout the 36-week follow-up
|
Throughout the 36-week follow-up
|
|
Buprenorphine acceptability
Time Frame: Week 36
|
The proportion of participants who initiate buprenorphine from among those randomized to the Buprenorphine group.
|
Week 36
|
Buprenorphine tolerability
Time Frame: Week 36
|
The proportion of patients who do not discontinue buprenorphine due to adverse effects or intolerance.
|
Week 36
|
Overall Sense of Quality of Life
Time Frame: Weeks 12, 24, and 36
|
Quality of life will be measured using the Single-Item QOL Scale (SIS) from McGill Quality of Life (MQOL) questionnaire.
Lowest score - 0; highest score - 10; Higher score equals better outcome.
|
Weeks 12, 24, and 36
|
Physical Functioning
Time Frame: Weeks 12, 24, and 36
|
Physical functioning will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Functioning Short Form (SF)-6b questionnaire.
Lowest score - 6; Highest score - 30; Higher score equals better outcome.
|
Weeks 12, 24, and 36
|
Depression
Time Frame: Weeks 12, 24, and 36
|
Depression will be measured using the Patient Health Questionnaire (PHQ)-9.
Lowest score - 0; Highest score - 27; Lower score equals better outcome.
|
Weeks 12, 24, and 36
|
Anxiety
Time Frame: Weeks 12, 24, and 36
|
Anxiety will be measured using the Generalized Anxiety Disorder (GAD)-7 questionnaire.
Lowest score - 0; Highest score - 21; Lower score equals better outcome.
|
Weeks 12, 24, and 36
|
Coping
Time Frame: Weeks 12, 24, and 36
|
Coping will be measured using the 1-Item Coping Strategies Questionnaire (CSQ).
Lowest score - 0; Highest score - 6; Lower score equals better outcome.
|
Weeks 12, 24, and 36
|
Sleep Quality
Time Frame: Weeks 12, 24, and 36
|
Sleep quality will be measure using the PROMIS Sleep Disturbance Short Form (SF) 6a and the Sleep Duration Question. PROMIS Sleep Disturbance SF 6a: Lowest score - 6; Highest score - 30; Lower score equals better outcome. Sleep Duration Question: Reported in hours and minutes of sleep; Higher number equals better outcome. |
Weeks 12, 24, and 36
|
Fatigue
Time Frame: Weeks 12, 24, and 36
|
Fatigue will be measured using the PROMIS Fatigue Short Form (SF) 6a.
Lowest score - 6; Highest score - 30; Lower score equals better outcome.
|
Weeks 12, 24, and 36
|
Satisfaction with Treatment
Time Frame: Weeks 12, 24, and 36
|
Satisfaction will be measured using the Patient Global Impression of Change (PGIC).
Lowest score - 1; Highest score - 7; Lower score equals better outcome.
|
Weeks 12, 24, and 36
|
Social Support
Time Frame: Weeks 12, 24, and 36
|
Social support will be measured using the Multidimensional Scale of Perceived Social Support (MSPSS).
Lowest score - 7; Highest score - 7; Higher score equals better outcome.
|
Weeks 12, 24, and 36
|
Family Intrusion
Time Frame: Weeks 12, 24, and 36
|
Family intrusion will be measured using the PROMIS Satisfaction with Social Roles and Activities.
Lowest score - 8; Highest score - 40; Higher score equals better outcome.
|
Weeks 12, 24, and 36
|
Self-Efficacy
Time Frame: Weeks 12, 24, and 36
|
Self-efficacy will be measured using the PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 8A and the Single item targeting self-efficacy for pain. PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 8A: Lowest score - 8; Highest score - 40; Higher score equals better outcome. Single item targeting self-efficacy for pain: Lowest score - 0; Highest score - 100; Higher score equals better outcome. |
Weeks 12, 24, and 36
|
Other Symptoms
Time Frame: Weeks 12, 24, and 36
|
Other symptoms will be measured using the Dialysis Symptom Index (DSI).
Lowest score - 0; Highest score - 150; Lower score equals better outcome.
|
Weeks 12, 24, and 36
|
Discrimination
Time Frame: Week 36
|
Discrimination will be measured using the Everyday Discrimination Scale Short Version (EDS-S).
Lowest score - 0; Highest score - 5; Lower score equals better outcome.
|
Week 36
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Laura Dember, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Substance-Related Disorders
- Kidney Diseases
- Urologic Diseases
- Pain
- Neurologic Manifestations
- Disease Attributes
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Narcotic-Related Disorders
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Chronic Pain
- Kidney Failure, Chronic
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
Other Study ID Numbers
- HOPE
- U01DK123813 (U.S. NIH Grant/Contract)
- U01DK123786 (U.S. NIH Grant/Contract)
- U01DK123787 (U.S. NIH Grant/Contract)
- U01DK123812 (U.S. NIH Grant/Contract)
- U01DK123814 (U.S. NIH Grant/Contract)
- U01DK123816 (U.S. NIH Grant/Contract)
- U01DK123817 (U.S. NIH Grant/Contract)
- U01DK123818 (U.S. NIH Grant/Contract)
- U01DK123821 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
Clinical Trials on Pain Coping Skills Training (PCST)
-
Wake Forest University Health SciencesHonorHealth Research InstituteRecruitingCIPN - Chemotherapy-Induced Peripheral NeuropathyUnited States
-
Duke UniversityCompletedPCST-Full (Pain Coping Skills Training) | PCST-BriefUnited States
-
Duke UniversityCompletedMobile Pain Coping Skills Training | In Person Pain Coping Skills TrainingUnited States
-
Duke UniversityCompletedStem Cell TransplantUnited States
-
University of North Carolina, Chapel HillPatient-Centered Outcomes Research InstituteCompletedOsteoarthritisUnited States
-
Duke UniversityAmerican Cancer Society, Inc.RecruitingPain | Advanced Solid TumorUnited States
-
Duke UniversityIcahn School of Medicine at Mount SinaiCompleted
-
Duke UniversityRecruitingBreast CancerUnited States
-
Wake Forest University Health SciencesNorthwestern University; Duke UniversityWithdrawnChronic Migraine, Headache
-
Virginia Commonwealth UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedKnee OsteoarthritisUnited States